Population pharmacokinetics of extended-infusion piperacillin-tazobactam in hospitalized patients with nosocomial infections

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 8, 2012, Pages 4087-4094

  Felton, T W ^a   Hope, W W ^a   Lomaestro, B M ^c   Butterfield, J M ^b   Kwa, A L ^d   Drusano, G L ^e   Lodise, T P ^b  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c ALBANY MEDICAL CENTER   (United States)

^d SINGAPORE GENERAL HOSPITAL   (Singapore)

^e UNIVERSITY OF FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PIPERACILLIN PLUS TAZOBACTAM;

ADULT; ANTIBIOTIC THERAPY; ARTICLE; CLINICAL ARTICLE; DRUG CLEARANCE; FEMALE; HOSPITAL INFECTION; HUMAN; INFUSION; MALE; MICHAELIS CONSTANT; MINIMUM INHIBITORY CONCENTRATION; MONTE CARLO METHOD; PRIORITY JOURNAL;

ADULT; ANTI-BACTERIAL AGENTS; CROSS INFECTION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HOSPITALIZATION; HUMANS; INFUSIONS, INTRAVENOUS; MALE; METABOLIC CLEARANCE RATE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MONTE CARLO METHOD; PENICILLANIC ACID; PIPERACILLIN; YOUNG ADULT;

EID: 84864390325     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00521-12     Document Type: Article

References (28)

1. Akaike H. 1979. A Bayesian extension of the minimum AIC procedure of autoregressive model fitting. Biometrika 66:237.
2. Auclair B, Ducharme MP. 1999. Piperacillin and tazobactam exhibit linear pharmacokinetics after multiple standard clinical doses. Antimicrob. Agents Chemother. 43:1465-1468. (Pubitemid 29259345)
3. Bergan T, Williams JD. 1982. Dose dependence of piperacillin pharmacokinetics. Chemotherapy 28:153-159. (Pubitemid 12127444)
4. Blondiaux N, et al. 2010. Daily serum piperacillin monitoring is advisable in critically ill patients. Int. J. Antimicrob. Agents 35:500-503.
5. Bulitta JB, et al. 2007. Systematic comparison of the population pharmacokinetics and pharmacodynamics of piperacillin in cystic fibrosis patients and healthy volunteers. Antimicrob. Agents Chemother. 51:2497-2507. (Pubitemid 47047329)
6. Bulitta JB, et al. 2010. Nonlinear pharmacokinetics of piperacillin in healthy volunteers-implications for optimal dosage regimens. Br. J. Clin. Pharmacol. 70:682-693.
7. Conil J-M, et al. 2006. Influence of renal function on trough serum concentrations of piperacillin in intensive care unit patients. Intensive Care Med. 32:2063-2066. (Pubitemid 44833123)
8. Cox HJ, Bhandari S, Rigby AS, Kilpatrick ES. 2008. Mortality at low and high estimated glomerular filtration rate values: a "U" shaped curve. Nephron. Clin. Practice 110:c67-c72.
9. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1-10.
10. D'Argenio DZ, Schumitzky A. 1979. A program package for simulation and parameter estimation in pharmacokinetic systems. Computer Programs Biomed. 9:115-134. (Pubitemid 9104986)
11. D'Argenio DZ, Schumitzky A, Xiaoning W. 2009. ADAPT 5 user's guide: pharmacokinetic/pharmacodynamic systems analysis software. Biomedical Simulations Resource, Los Angeles, CA.
12. Drusano GL. 2004. Antimicrobial pharmacodynamics: critical interactions of "bug and drug." Nat. Rev. Microbiol. 2:289-300. (Pubitemid 39490099)
13. Fuster-Lluch O, Gerónimo-Pardo M, PeyrÓ-García R, Lizán-García M. 2008. Glomerular hyperfiltration and albuminuria in critically ill patients. Anaesth. Intensive Care 36:674-680.
14. Hayashi Y, Ja Roberts Paterson DL, Lipman J. 2010. Pharmacokinetic evaluation of piperacillin-tazobactam. Expert Opin. Drug Metab. Toxicol. 6:1017-1031.
15. Kim M-K, et al. 2002. Pharmacokinetic and pharmacodynamic evaluation of two dosing regimens for piperacillin-tazobactam. Pharmacotherapy 22:569-577. (Pubitemid 34464943)
16. Kuck NA, Jacobus NV, Petersen PJ, Weiss WJ, Testa RT. 1989. Comparative in vitro and in vivo activities of piperacillin combined with the beta-lactamase inhibitors tazobactam, clavulanic acid, and sulbactam. Antimicrob. Agents Chemother. 33:1964-1969. (Pubitemid 19268365)
17. Lister PD, Prevan M, Sanders CC. 1997. Importance of beta-lactamase inhibitor pharmacokinetics in the pharmacodynamics of inhibitor-drug combinations: studies with piperacillin-tazobactam and piperacillin-sulbactam. Antimicrob. Agents Chemother. 41:721-727. (Pubitemid 27150519)
18. Lodise TP, Jr, Lomaestro B, Rodvold KAA, Danziger LH, Drusano GL. 2004. Pharmacodynamic profiling of piperacillin in the presence of tazobactam in patients through the use of population pharmacokinetic models and Monte Carlo simulation. Antimicrobial agents and chemotherapy. Am. Soc. Microbiol. 48:4718-4724. (Pubitemid 39577677)
19. Neely MN, van Guilder M, Yamada W, Schumitzky A, Jelliffe R. Accurate detection of outliers and subpopulations with Pmetrics: a non-parametric and parametric pharmacometric modeling and simulation package for R. Ther. Drug Monit., in press.
20. R Development Core Team. 2011. R: a language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria.
21. Rello J, et al. 2010. Determinants of choice and prescription patterns in empiric antibiotic therapy for HAP/VAP. J. Eur. Resp. Soc. 37:1332-1339.
22. Roberts JA, Hope WW, Lipman J. 2010. Therapeutic drug monitoring of beta-lactams for critically ill patients: unwarranted or essential? Int. J. Antimicrob. Agents 35:419-420.
23. Roberts JA, Kirkpatrick CMJ, Roberts MS, Dalley AJ, Lipman J. 2010. First-dose and steady-state population pharmacokinetics and pharmacodynamics of piperacillin by continuous or intermittent dosing in critically ill patients with sepsis. Int. J. Antimicrob. Agents 35:156-163.
24. Roberts JA, Lipman J. 2009. Pharmacokinetic issues for antibiotics in the critically ill patient. Crit. Care Med. 37:840-851.
25. Sörgel F, Kinzig M. 1993. The chemistry, pharmacokinetics and tissue distribution of piperacillin/tazobactam. J. Antimicrob. Chemother. 31(Suppl. A):39-60. (Pubitemid 23078096)
26. Tam VH, Preston SL, Drusano GL. 2003. Optimal sampling schedule design for populations of patients. Antimicrob. Agents Chemother. 47:2888-2891. (Pubitemid 37040264)
27. Udy Aa et al. 2011. Sub-therapeutic initial β-lactam concentrations in select critically ill patients: association between augmented renal clearance and low trough drug concentrations. Chest doi:10.1378/chest.11-1671. [Epub ahead of print.]
28. Vinks AA, den Hollander JG, Overbeek SE, Jelliffe RW, Mouton JW. 2003. Population pharmacokinetic analysis of nonlinear behavior of piperacillin during intermittent or continuous infusion in patients with cystic fibrosis. Antimicrob. Agents Chemother. 47:541-547. (Pubitemid 36158079)